NEW YORK, Sept. 07, 2016 (GLOBE NEWSWIRE) — Actinium Pharmaceuticals, Inc. (NYSE MKT:ATNM) (“Actinium” or “the Company”), a biopharmaceutical Company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers, announced today that it has added two industry veterans to its product development and clinical development teams. J.C. Simeon has joined Actinium’s product development team as Executive Director of Quality Assurance and will report to Kaushik J. Dave, Ph.D., MBA, Actinium’s CEO. In addition, Karen Louw has joined Actinium’s clinical development team as Clinical Research Associate and will report to Felix Garzon, M.D., Ph.D., Actinium’s Senior Vice President and Head of Clinical Development.
“We are excited to welcome J.C. and Karen to the Actinium team and are pleased with our continued ability to attract top talent,” said Sandesh Seth, Actinium’s Executive Chairman. “Throughout his career J.C. has displayed a consistent ability to effectively manage the production of pharmaceutical products in a timely manner with a very high level of quality, which will serve Actinium well as we ramp up our activity for our current clinical trials and look ahead to the future with the potential for commercial product. Karen’s clinical and nursing experience provides excellent value to our clinical development team. She will have a positive impact on the initiation of clinical trial sites and on the efficient execution of our clinical trials.”
J.C. will be responsible for ensuring the quality and timely manufacturing of Actinium’s products through the supervision and management of Actinium’s external contract manufacturing organization (CMO) relationships with a focus on process development, optimization and the implementation of quality systems management J.C. joins Actinium from Qualitest, an Endo Pharmaceutical Company, where he held the position of Director of Quality, External Manufacturing with a focus on commercial products and generics R&D. In this role J.C. was responsible for managing the external manufacturing quality assurance for over 300 products spanning 40 contract manufacturing organizations (CMO) located in the U.S. and internationally. Prior to Qualitest, J.C. was Associate Director, Quality Management Commercial Operations & Products for Otsuka America Pharmaceutical, Inc. Prior to Otsuka, J.C. worked at Cephalon, Inc. for almost 8 years in several quality assurance positions, culminating as Associate Director, Quality Assurance. In addition, he worked Cardinal Health, Inc. J.C. holds a B.S. in chemical engineering and an M.S. in biomedical engineering from New Jersey Institute of Technology. He also holds a Certificate in Clinical Development and Regulatory Affairs.
As Clinical Research Associate at Actinium, Karen will support the progress of Actinium’s clinical trials by providing direct training to clinical trial site staff, implementing protocol and training materials and serving as a clinical expert for patient monitoring and safety. Karen joins Actinium from Columbia University Medical Center where she held the position of Clinical Research Nurse in the thoracic oncology and hematology/oncology divisions. In addition, she worked as a Clinical Nurse in the oncology and bone marrow transplant unit at New York-Presbyterian/Columbia University Medical Center. Prior to this role, Karen worked as a registered nurse with a focus on oncology. Karen holds a B.S. in Nursing from the University of Wisconsin and holds an Adult & Geriatric Nurse Practitioner degree from Hunter College. She is a licensed nurse in the states of New York and Wisconsin and is a licensed nurse practitioner in the state of New York.
About Actinium Pharmaceuticals
Actinium Pharmaceuticals, Inc. (www.actiniumpharma.com) is a New York-based biopharmaceutical company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers. Actinium’s targeted radioimmunotherapy products are based on its proprietary delivery platform for the therapeutic utilization of alpha-emitting Actinium-225 and Bismuth-213 and certain beta emitting radiopharmaceuticals in conjunction with monoclonal antibodies. The Company’s lead radiopharmaceutical product candidate Iomab-B is designed to be used, upon approval, in preparing patients for hematopoietic stem cell transplant, commonly referred to as bone marrow transplant. The Company is conducting a single, pivotal, multicenter Phase 3 clinical study of Iomab-B in refractory or relapsed AML patients over the age of 55 with a primary endpoint of durable complete remission. The Company’s second product candidate, Actimab-A, is continuing its clinical development in a Phase 1/2 trial for patients newly diagnosed with AML over the age of 60 in a single-arm multicenter trial.
Forward-Looking Statements for Actinium Pharmaceuticals, Inc.
This news release contains “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995. These statements are based on management’s current expectations and involve risks and uncertainties, which may cause actual results to differ materially from those set forth in the statements. The forward-looking statements may include statements regarding product development, product potential, or financial performance. No forward-looking statement can be guaranteed and actual results may differ materially from those projected. Actinium Pharmaceuticals undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise.
CONTACT: Contact: Steve O'Loughlin Vice President, Finance and Corporate Development Actinium Pharmaceuticals, Inc. soloughlin@actiniumpharma.com
